ArticleClinical and vaccine immunology : CVI2016

CCL19 as a Chemokine Risk Factor for Posttreatment Lyme Disease Syndrome: a Prospective Clinical Cohort Study.

John N Aucott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.